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Objective: To explore the possibility of diagnosing and monitoring patients 
with systemic lupus erythematosus (SLE) using the combination of mean 
platelet volume (MPV) and routine immunoglobulin test. Methods: 116 
patients with SLE were divided into 3 groups according to their clinical 
characteristics, including 29 patients with renal impairment, 44 cases of 
active stage and 43 cases of inactive patients. 40 healthy subjects were ran-
domly selected as controls. Subjects were tested for routine blood test and 
plasma Immunoglobins, such as IgG, IgA, IgM, C3, C4, CH50, CRP. The 
results were analyzed and the characteristics of each group of subjects were 
determined, the correlation between test results and diagnosis were studied. 
Results: In comparison to the control group, the serum level of MPV, C3 
and C4 were decreased (P<0.05), and C reactive protein level was elevated 
(P<0.001) in the three groups of SLE patients. The IgG level in active and 
inactive SLE patients was increased (P<0.0001), CH50 level was decreased 
in patients with inactive SLE (P<0.05), IgA level of active SLE subjects 
was found to be elevated (P<0.05), IgM in patients with renal impairment 
was decreased (P<0.05). Other than that, no other signi cant characteristic 
were found. Conclusion: The pathogenesis of SLE is a complex process 
involving multiple factors. The changes of MPV, IgG, IgA, IgM, C3, C4, 
CH50 and CRP in SLE patients are characteristic parameters. The combina-
tion of the above indicators can help to determine the diagnosis and staging 
of SLE. The timely diagnosis and treatment of SLE patients has important 
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1. Introduction
S
ystemic lupus erythematosus is a recurrent and re-
lapsing autoimmune disorder that invades the skin 
and multiple organs[1]. At present, the exact cause 
of SLE has not been fully elucidated. SLE patients exhibit 
numerous aberrations in the immune system. In this study, 
we examined routine blood test and plasma Immunoglo-
bins, such as IgG, IgA, IgM, C3, C4, CH50, CRP in SLE 
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patients and healthy controls, exploring the characteristics 
of the above results in patients with SLE at different stag-
es, providing a new reference for the diagnosis and treat-
ment of SLE.
2. Materials and Methods
2.1 Subjects  
116 SLE patients admitted to the Department of Rheuma-
tology, Nephrology, and Dermatology of Lingnan Hospi-
tal from January 2012 to December 2016, were selected 
for this study. There were 106 females and 10 males, aged 
between 15 and 73 years, with an average age of 34.0 ± 
13.0 years. All subjects met the SLE diagnostic criteria 
revised by the American College of Rheumatology (ACR) 
in 1997[2]. None of the patients received anti-lupus treat-
ment before admission. 
Patients with other diseases, such as dyslipidemia, 
blood system diseases, in ammatory diseases, etc. are 
excluded. The activity of SLE was evaluated by sys-
temic lupus erythematosus disease activity index (SLE-
DAI). SLE-DAI≥10 were defined active SLE group, 
and SLEDAI<10 were de ned in inactive SLE group. 
73 patients were in the active SLE group, including 29 
patients with renal impairment (LN) and 44 patients 
without renal impairment, and there were 43 cases in 
the non-active period group. 40 healthy controls were 
randomly selected as controls, including 9 males and 
31 females with an average age of (30.2±6.6) years. 
There were no significant differences in gender, age, 
BMI, etc. between the active SLE group, SLE active 
with renal injury group, the inactive SLE group and the 
control group (P>0.05). 
2.2 Methods
6 mL of venous blood sample were collected from each 
test subjects in fasting state on second morning of ad-
mission, or at 9am on the day of the medical examina-
tion. Each blood sample was dispensed into 3 tubes, and 
corresponding pretreatment was performed according 
to the purpose of the test. IgG, IgA, IgM, C3, C4, CH50 
and C-reactive protein (CRP) levels were measured by 
immunoturbidimetry using a automatic biochemical ana-
lyzer(Hitachi 7180, Japan) , and the routine blood test was 
performed using automatic blood cell meter(Sysmex XE-
5000, Japan) . 
All tests and result interpretation were operated in strict 
accordance with the procedures instructions, all reagents 
used were within the validity period.
2.3 Statistical Analysis
Statistical analysis was performed using SPSS 13.0 soft-
ware. Inter-group comparisons of measurement data were 
performed using unpaired t-test, and Spearman rank cor-
relation analysis were performed. 
Table 1. Comparison of different SLE groups and healthy controls




in-active SLE 43 9.669±0.139a 17.85±1.497a 2.36±0.155 1.069±0.084 0.581±0.039a 0.122±0.014a 29.16±2.268a 4.336±1.041a
active SLE 44 9.824±0.135a 16.88±0.943a 2.506±0.127a 1.037±0.105 0.713±0.049a 0.156±0.018a 33.41±2.633a 8.676±2.107a
active SLE plus 
renal impairment
29 9.558±0.124a 10.77±1.149 1.93±0.169 0.792±0.095a 0.668±0.044a 0.156±0.016a 36.07±3.003 6.617±1.414a
Control 40 10.48±0.144 12.24±0.337 2.04±0.075 1.126±0.063 1.029±0.027 0.240±0.009 37.2±0.999 1.399±0.273
Notes: a: compared with healthy controls, P < 0.05.
Table 2. Comparison of inactive SLE group, active SLE plus renal impairment group, and active SLE group




inactive SLE 43 9.669±0.139 17.85±1.497 2.36±0.155 1.069±0.084 0.581±0.039a 0.122±0.014 29.16±2.268 4.336±1.041
active SLE 44 9.824±0.135 16.88±0.943 2.506±0.127 1.037±0.105 0.713±0.049 0.156±0.018 33.41±2.633 8.676±2.107
active SLE plus 
renal impairment
29 9.558±0.124 10.77±1.149a 1.93±0.169a 0.792±0.095 0.668±0.044 0.156±0.016 36.07±3.003 6.617±1.414
Notes: a: compared with the active SLE group, P < 0.05.
DOI: https://doi.org/10.30564/jams.v2i4.1228
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3. Results
3.1 Comparison of Different SLE Groups and 
Healthy Controls
MPV, C3 and C4 were decreased (P<0.05), and CRP was 
increased (P<0.001) in the in-active SLE group, active 
SLE group, active SLE plus renal impairment group. 
The IgG level in active and inactive SLE patients was in-
creased (P<0.0001), CH50 level was decreased in patients 
with inactive SLE (P<0.05), IgA level of active SLE sub-
jects was found to be elevated (P<0.05), IgM in patients 
with renal impairment was decreased (P<0.05). See the 
table below.
3.2 Comparison between Different SLE Groups
As shown in the table below, C3 were increased in the in-
active SLE group (P<0.05), compared with the active SLE 
group, both IgG and IgA were decreased in the active SLE 
subjects but not in the active SLE plus renal impairment 
group (P<0.01; P<0.05).
4. Discussion
At present, the etiology of SLE is still unclear. It is an 
immune disease characterized by multiple system damage 
and accompanied by a variety of autoantibodies. The main 
clinical symptoms of SLE include joint pain, fever, skin 
erythema, etc[3]. Hematological damage also is a common 
manifestation. Studies have shown that SLE may devel-
op immune-mediated leukopenia, thrombocytopenia and 
anemia[4], among which thrombocytopenia is the most 
common, accounting for about 7% to 30% of all cases. In 
SLE patients, it is an important cause of death. A careful 
observation of peripheral blood cells parameters is neces-
sary for early detection and a proper assessment of SLE 
progression and prognosis[5]. The reduction of platelet 
count in patients with SLE has become a consensus[6]. In 
this study, we found that platelet mean volume decreased 
in patients with SLE. Size and volume are closely relat-
ed to the ultrastructure, enzyme activity and functional 
status of platelets. Bulk platelets contain more glycogen, 
adenine, nucleotides and orthophosphate, are also more 
active. A decrease in platelet volume indicates a decrease 
in tangible substances, activity, and function. In this study, 
the MPV of SLE patients were signi cantly reduced com-
pared with the control group, indicating that the reduction 
of the number and volume of platelets in SLE patients 
may cause platelet dysfunction.
The serum markers for clinical diagnosis of SLE are 
mainly autoantibodies and in ammatory factors. Autoanti-
bodies are speci c for the diagnosis of SLE. It is generally 
believed that when used to diagnose SLE, anti-nuclear 
antibody (ANA) is more sensitive, but has lower speci c-
ity. If it is tested alone, it can only be used as a screening 
test. Anti-Smith(Sm) antibody, anti-double strand DNA( 
dsDNA) antibody, anti-nucleosome antibody( AnuA) and 
anti-ribosomal P protein antibody were some speci c indi-
cator for the diagnosis of SLE. However, the positive rates 
of Anti-Smith(Sm) antibody, anti-double strand DNA( 
dsDNA) antibody are 37.9% and 32.7%, respectively[7], so 
that even though the diagnosis of SLE with both of them 
has greater speci city, but the diagnostic sensitivity is low, 
easy to miss, and the project is dif cult for primary clinics 
to practice.
Our study found that the serum levels of C3 and C4 in 
the three groups of SLE patients were decreased. This may 
be because a large number of circulating immune com-
plexes were formed in the patient, complement system 
were activated and thus consumed a large amount of com-
plement C3, C4, which is consistent with other studies[8,9]. 
The increase in CRP also re ects the state of immune dys-
function. We have found that IgG and IgA produced by B 
cells from patients with SLE increased to varying degrees, 
indicating that the humoral immune system is hyperactive. 
In the inactive group, IgG was increased, while IgA was 
increased in active SLE patients, and IgM was decreased 
in active plus renal injury group, suggesting that there is 
a certain correlation between immunoglobulin levels and 
disease activity. Dynamic observation of changes in serum 
immunoglobulin levels may be helpful in analyzing dis-
ease progression[10].
5. Conclusion
In summary, this study found that levels of C3 and C4 
were reduced in different subgroups of SLE patients with 
a different but characteristic immunoglobulin change. If 
supported by a larger sample of clinic data, these speci c 
changes, combined with other examinations and clinic 
symptoms and signs, may have a significant value for 
the diagnosis and staging of SLE, thereby improving the 
prognosis of this complicated disease.
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